Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
PLoS One. 2017 Oct 18;12(10):e0186620. doi: 10.1371/journal.pone.0186620. eCollection 2017.
The mechanism of action of histone deacetylase inhibitors (HDACi) is mainly attributed to the inhibition of the deacetylase catalytic activity for their histone substrates. In this study, we analyzed the abundance of class I HDACs in the cytosolic, nuclear soluble and chromatin bound cellular fractions in breast cancer cells after HDACi treatment. We found that potent N-hydroxy propenamide-based HDACi induced a concentration dependent decrease in the HDAC1 associated with chromatin and a lasting concomitant increase in cytoplasmic HDAC1 while maintaining total protein expression. No such change occurred with HDAC2 or 8, however, an increase in cytoplasmic non-phosphorylated HDAC3 was also observed. The subcellular re-equilibration of HDAC1 was subsequent to the accumulation of acetylated histones and might be cell cycle dependent. This study suggests that the biological activity of a subset of N-hydroxy propenamide-based HDACi may stem from direct competition with histone substrates of HDACs as well as from spatial separation from their substrates in the nucleus and/or change in post-translational modification status of HDACs.
组蛋白去乙酰化酶抑制剂(HDACi)的作用机制主要归因于其对组蛋白底物的去乙酰化酶催化活性的抑制。在这项研究中,我们分析了乳腺癌细胞在 HDACi 处理后细胞溶质、核可溶和染色质结合细胞分数中 I 类 HDAC 的丰度。我们发现,强效的 N-羟基丙烯酰胺基 HDACi 诱导与染色质相关的 HDAC1 浓度依赖性降低,并持续伴随细胞质 HDAC1 的增加,同时保持总蛋白表达。然而,HDAC2 或 8 没有发生这种变化,细胞质非磷酸化 HDAC3 的增加也观察到了。HDAC1 的亚细胞再平衡发生在乙酰化组蛋白的积累之后,可能与细胞周期有关。这项研究表明,一组 N-羟基丙烯酰胺基 HDACi 的生物学活性可能源于与 HDAC 的组蛋白底物的直接竞争,以及与核内的底物在空间上的分离和/或 HDAC 的翻译后修饰状态的改变。